Ashland expands polyvinyl pyrrolidone production

14-Feb-2012 - USA

Ashland Inc. s responding to strong demand for Plasdone™ polyvinyl pyrrolidone (PVP) by adding new low-viscosity, pharmaceutical-grade PVP capacity at its manufacturing facility in Calvert City, Ky., U.S.A. The new capacity will further strengthen Ashland’s position in the market and will enable the company to continue supporting the growing needs of its pharmaceutical customers.  The additional capacity is currently being validated for pharmaceutical-grade PVP production and will be available for sale to Ashland’s pharmaceutical customers in March 2012.

Plasdone PVP is a synthetic polymer used globally as a tablet binder in a wide variety of over-the-counter and prescription drug products.  As a global leader, Ashland currently produces PVP at its manufacturing facilities in Calvert City, Ky. and Texas City, Texas, U.S.A. enabling Ashland to respond to changing market requirements and increase the security of supply to its customers.

 “Over the next few years, Ashland expects steady growth in PVP driven by an industry need for formulation ingredients that improve the quality of finished drug products,” added Jeff Wolff, group vice president, Pharmaceutical and Nutritional Specialties, Ashland Specialty Ingredients.  “We see particularly strong growth in emerging markets, generated by increased demand for generic drug products and consumer demographics. Combining our industry-leading position as a producer of PVP with our multiple technical support labs around the world, Ashland is well suited to meet this increasing market demand.”

Other news from the department manufacturing

Most read news

More news from our other portals

Discover the latest developments in battery technology!